Drug maker Dr Reddy's Laboratories today said its Mexican arm has received a warning letter from the US health regulator for violation of current goods manufacturing practice regulations.
Industrias Quimicas Falcon de Mexico SA has received a warning letter -- on four counts -- from the US Food and Drug Administration (USFDA), Dr Reddy's said in a statement.
The company's Mexico facility produces intermediates and active pharmaceutical ingredients.
The USFDA had inspected Dr Reddy's Mexico facility in November 2010 and later sought certain explanations from the company. However, the regulator issued the warning letter dated June 3, citing "lack of corrective actions" by the firm.
"Dr Reddy's felt it responded to the 483 observations by implementing a number of corrective actions. However, the USFDA has asked for additional data and corrective actions to the items listed in the warning letter," the company said.
The Hyderabad-based firm said it takes these matters seriously and will respond to the USFDA within the stipulated time frame.
More From This Section
"Dr Reddy's looks forward to working collaboratively with the USFDA to resolve the matters contained in the warning letter," it added.
The four counts include non-validation of analytical methods used to test APIs.
USFDA has inspected the Mexico facility during November 8-11, 2010 and identified significant deviations from Current Good Manufacturing Practice (CGMP) for the manufacture of APIs.
"The inspection revealed that your firm had not validated the HPLC method for assay and related substances of fluocinolone acetonide [finished API steroid for human use]," USFDA's letter said.
"This is just one example of numerous methods used by your firm that had not been validated according to approved procedures," it added.
Shares of Dr Reddy's Laboratories today closed at Rs 1,554.60 a piece on the Bombay Stock Exchange, up 1% from the previous close.